[1] Bray F,Ferlay J, Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68:394-424. [2] Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation[J]. Cell,2011,144: 646-674. [3] Nguyen PM, Putoczki TL. Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?[J]. Cytokine,2018,8:1-11. [4] 杜奕奇,蔡全才,廖专,等.中国早期胃癌筛查流程专家共识意见(草案)(2017年,上海)[J].胃肠病学,2018,23:92-97. [5] 丁霞,魏玮,沈洪,等.从中医学视角看慢性胃炎“炎-癌转化”[J].北京中医药大学学报,2018,41:885-889. [6] 袁嘉嘉,顾超,孙志广,等.“炎-癌转化”的病因病机——以慢性萎缩性胃炎为例[J].长春中医药大学学报,2018,34:624-626. [7] Kuwabara T,Ishikawa F,Kondo M,et al. The role of IL-17 and related cytokines in inflammatory autoimmune diseases[J].Mediators Inflamm, 2017, 2017: 3908061.doi:10.1155/2017/3908061. [8] J.Zhang,Q Qiao,M Liu, T,et al. IL-17 promotes scar formation by inducing macrophage infiltration[J].Am J Pathol, 2018,188:1693-1702. [9] Song Y, Yang JM. Role of interleukin(IL)-17and T-helper(Th)17 cells in cancer[J].Biochem Biophys Res Commun,2017,493:1-8. [10] Hnatyszyn A, Wielgus K, Kaczmarek-Rys M, et al. Interleukin-1 gene polymorphisms in chronic gastritis patients infected with helicobacter pylori as risk factors of gastric cancer development[J].Arch Immunol Ther Exp(Warsz),2013,61:503-512. [11] Jiang G,Liu CT,Zhang WD.IL-17A and GDF15 are able to induce epithelial-mesenchymal transition of lung epithelial cells in response to cigarette smoke[J].Exp Ther Med, 2018, 16: 12-20. [12] Molina MF, Abdelnabi MN, Fabre T,et al. Type 3 cytokines in liver fibrosis and liver cancer[J]. Cytokine,2018,28:1-11. [13] Chen R,Chen QT,Dong YH. Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17[J]. Oncol Lett,2019,17:5447-5452. [14] 陈锦霞,单保恩,李清靖,等.IL-17及其相关分子在胃癌组织中的表达和相关性分析[J].肿瘤学杂志,2019,25:537-540. [15] 周勇旭,张岩,张霞,等.胃癌患者血清IL-17表达及与VEGF相关性分析[J].哈尔滨医科大学学报,2018,52:354-357. |